Mechanism of treating breakthrough pain of CIBP through a transient reversal of the sodium-calcium exchangers

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027672

Enrollment

Unknown

Registered

2019-11-23

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer-induced bone pain

Interventions

Group 2:Morphine combined with bupivacaine group

Group 1:Morphine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) although the patient receives medication, the pain is not fully controlled; (2) unable to tolerate opioid titration scheme due to side effects; (3) patients may prefer intrathecal administration

Exclusion criteria

Exclusion criteria: (1) patients with coagulation dysfunction, spinal metastasis at the puncture site, spinal infection at the puncture site, severe scoliosis of the spine, who have undergone intraspinal surgery and other procedures unsuitable for intraspinal canal analgesia; (2) patients who do not accept intravertebral canal analgesia operation

Design outcomes

Primary

Measure	Time frame
Plasma endorphins;Plasma motilin;Substance P of cerebrospinal fluid;Cerebrospinal fluid tumor necrosis factor;CSF calcitonin gene-related peptide;CSF prostaglandin E2;Na+-K+-ATPase;Ca2+-ATPase;	—

Countries

China

Contacts

Public ContactZhang Xianhong

Cancer Hospital of Hu'nan

zhangxianhong@hnca.org.cn+86 15973188862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026